Elysium Health™ Announces Positive Data on Its Product BASIS Published in "Nature Partner Journals: Aging and Mechanisms of Disease"

NEW YORK, Nov. 27, 2017 /PRNewswire-USNewswire/ -- Elysium Health, Inc.,™ a consumer health company developing scientifically-sound natural health products, today announced that detailed results from its clinical trial on BASIS ™ were published in Nature Partner Journals: Aging and Mechanisms of Disease. The article entitled, "Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study," is now available online [https://www.nature.com/articles/s41514-017-0016-9]. BASIS is a daily supplement consisting of nicotinamide riboside (NR), an NAD+ precursor vitamin found in milk, and pterostilbene, a polyphenol found in blueberries.

"We are very pleased to present the detailed findings from our clinical trial on BASIS in the peer-reviewed journal Nature Partner Journals: Aging and Mechanisms of Disease," said Dr. Leonard Guarente, Novartis professor of biology and the Director of the Glenn Laboratory for the Science of Aging Research at MIT, as well as the co-founder and Chief Scientist at Elysium Health. "Our company is founded on the belief that scientific breakthroughs and research should be accessible to consumers who want to take a proactive role in managing their health."

The first in-human clinical trial, designed to evaluate the safety and efficacy of BASIS, showed that repeat dose is a safe and effective way to increase and sustain NAD+ levels. This is the first-ever demonstration that NAD+ levels can be increased and sustained over a period of time – an important initial step in better understanding the role of NAD+ in health maintenance.

The study, randomized, double-blind, and placebo-controlled involved 120 healthy adults aged 60 to 80 in three treatment arms – placebo, BASIS at recommended dose and double-dose BASIS. All participants took their blinded supplement daily for 8 weeks. Analysis of NAD+ in whole blood demonstrated that BASIS significantly increases in NAD+ in a dose dependent manner after four weeks as compared to baseline and to place. The increase was sustained throughout the entire eight-week trial. There were no serious adverse events reported in the BASIS arms compared to the placebo group.

In addition, Elysium Health added two members to its world-renowned scientific advisory board. The new members include:

• Carolyn Bertozzi, Ph.D., the Anne T. and Robert M. Bass Professor of Chemistry and Professor of Chemical & Systems Biology and Radiology (by courtesy) at Stanford University, and an Investigator of the Howard Hughes Medical Institute. Dr. Bertozzi's research interests span the disciplines of chemistry and biology with an emphasis on studies of glycoscience pertinent to disease states. Her lab studies cancer immunology, mycobacterial infections and the rare hereditary disease NGly1, all of which involve altered glycosylation as a disease driver.  Innovations from her lab include biologics targeting glycoimmune checkpoints for cancer immune therapy, bioorthogonal chemistries for molecular imaging and antibody-drug conjugate synthesis, and point-of-care infectious disease diagnostics.
• Vera Gorbunova, Ph.D., Doris Johns Cherry, Professor of Biology at the University of Rochester. Dr. Gorbunova's research focuses on aging, DNA repair and cancer. Dr. Gorbunova studies age-related changes in repair of DNA double-strand breaks, as well as mechanisms of longevity and cancer resistance in long-lived mammals.

The scientific advisory board consists of many of the world's leading scientists, clinicians, health care providers and industry innovators, including Nobel laureates. The advisory board provides strategic counsel on the direction of the company, helps to identify emerging scientific areas of research, and supports the product portfolio and clinical program.

"Science is the cornerstone of our mission, and we are excited to continue to add scientific advisory board members whose work and counsel actively advance scientific breakthroughs," said Eric Marcotulli, CEO of Elysium Health. "The additions of Drs. Bertozzi and Gorbunova reflect not only our commitment to help people manage their health in a proactive way, but also our focus on exploring varied and strategic avenues and research that will advance our pursuit of extraordinary science."

About Elysium Health™

Elysium Health's mission is to solve the biggest challenges in health with science, to help people live healthier, longer lives. Working directly with the world's leading scientists and clinicians, Elysium Health translates advances in science and technology into effective, scientifically sound products that help people manage their health in an actionable way. Learn more at www.elysiumhealth.com.

SOURCE Elysium Health